Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02083692
Recruitment Status :
First Posted : March 11, 2014
Last Update Posted : October 19, 2016
Sidney Kimmel Cancer Center at Thomas Jefferson University
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )
The purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease TOMM20 expression in squamous carcinoma cells and decrease MCT4 expression in fibroblasts.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH
Age ≥ 18 years of age and ≤80 years old.
Newly diagnosed with HNSCC cancer.
No prior therapy for HNSCC cancer is permitted for enrollment in the trial.
All subjects must be able to comprehend and sign a written informed consent document.
Pregnant or may become pregnant during metformin administration.
On metformin for any reason during the preceding 4 weeks.
Diabetic patients are eligible if they are not taking metformin, insulin or sulfonylureas.
Received iodinated contrast dye less than 48 hours prior to screening meet a temporary exclusion criteria to receive metformin. These patients cannot start investigational metformin until 48 hours have elapsed from contrast administration. Subjects who are scheduled for iodinated contrast dye administration within 48 hours of definitive surgery are excluded.
Plasma alanine aminotransferase greater than 40 IU/dL.
Plasma aspartate aminotransferase greater than 45 IU/dL.
Plasma creatinine level greater than 1.3 mg/dL.
Plasma alkaline phosphatase greater than 190 IU/dL.
Plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis.
History of congestive heart failure.
Myocardial ischemia or peripheral muscle ischemia.
Sepsis or severe infection.
History of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
Scheduled for definitive HNSCC cancer surgical resection less than two weeks from enrollment or greater than five weeks from enrollment.
History of hepatic dysfunction or hepatic disease.
Excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men.
All medications are permitted except those that are contraindicated with metformin under current FDA recommendations.